AIM ImmunoTech Selected to Present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
AIM ImmunoTech Inc. announces Chris McAleer, Ph.D., to present at cancer research symposium and sponsorship of the event.
09/22/2023 - 09:05 AM
OCALA, Fla., Sept. 22, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced Chris McAleer, Ph.D., Scientific Officer of AIM will present at the 3rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 20-22, 2023. In addition to the presentation, the Company is proud to announce its sponsorship of the event.
Details for the presentation are as follows:
Title: Rintatolimod (Ampligen® ): Overview of Ampligen’s Clinical Progress in Oncology Presenter: Christopher McAleer, Ph.D.Session: Session 7: Team Science: National and International Collaborations with NGOs, Academia, Pharma, & BiotechDate: Friday, September 22, 2023
For more information about the conference, visit: https://www.roswellpark.org/msc-symposium .
The presentation will be available on the AIM website once presented at the conference.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on Twitter , LinkedIn , and Facebook .
AIM Rankings
#3581 Ranked by Stock Gains
AIM Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Ocala
About AIM
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as